Hi Guest Login
Home > Tests > EBV (Epstein Barr Virus), PCR > Gurgaon
₹6650 ₹5320
Report Time
Report by Wed/Sat after 7 pmFREE
Home Sample Collection
Age Group
Parameters Included
1
Recomended for
Both
Fasting
No Fasting Required
Report Time
Report by Wed/Sat after 7 pm
Exclusive Offer
₹5320
₹6650
FREE Home Sample Collection*
FREE Smart Report
Get a callback from our Health advisor.
Understanding the Test
Test Measures
City Price Info
The EBV PCR Test is a highly sensitive molecular diagnostic test used to detect the presence of Epstein-Barr Virus (EBV) DNA in clinical samples. For residents of Gurgaon, timely access to this crucial diagnostic tool is supported by convenient options like at-home sample collection. EBV is common but can reactivate in individuals with weakened immune systems (such as transplant recipients, HIV patients, or those on immunosuppressive therapy). This test helps identify active EBV infection or viral reactivation at an early stage, enabling timely diagnosis, monitoring, and management of potential complications like post-transplant lymphoproliferative disorder (PTLD), hepatitis, and neurological infections.
The EBV PCR Test measures the presence or absence of Epstein-Barr Virus (EBV) DNA in a patient's sample. Unlike quantitative tests that determine the viral load, this qualitative test confirms whether EBV genetic material is detectable, helping clinicians assess active infection, viral reactivation, or EBV-associated complications. In Gurgaon, quick turnaround times for these results support rapid clinical decision-making, guiding further investigations, monitoring high-risk patients, evaluating treatment response, and determining the need for therapeutic interventions in immunocompromised individuals.
The EBV PCR test is a molecular diagnostic tool that identifies the presence or absence of Epstein-Barr Virus (EBV) DNA in blood, cerebrospinal fluid (CSF), or tissue biopsies.
Unlike quantitative tests that measure viral load, PCR tests indicate only whether the virus is present or absent.
EBV is a common herpesvirus that infects most people and remains dormant in healthy individuals. In those with weakened immune systems, such as transplant recipients, HIV patients, or individuals on immunosuppressive therapy, EBV can reactivate and cause severe complications, including post-transplant lymphoproliferative disorder (PTLD), a potentially fatal lymphoma.
Post-transplant patients should undergo routine EBV testing even without symptoms, as reactivation can occur silently and lead to PTLD.
A persistent or unexplained fever lasting several days or weeks may signal EBV reactivation or early PTLD. This is especially concerning in immunocompromised individuals and requires prompt testing to determine the cause.
Enlarged, painless, or tender lymph nodes in the neck, armpits, or groin may indicate EBV-related lymphoproliferation. In transplant patients, this can be an early sign of PTLD and requires immediate investigation.
Persistent fatigue, weakness, and general malaise are common in EBV mononucleosis-like syndrome. These symptoms often last longer than typical viral infections, raising suspicion of EBV.
Severe sore throat, swollen tonsils, and difficulty swallowing may indicate acute EBV infection (infectious mononucleosis). In immunocompromised patients, symptoms may be more severe and prolonged.
Unintentional weight loss and drenching night sweats are systemic symptoms that may be linked to EBV-driven PTLD or lymphoma, particularly in transplant recipients and HIV patients.
Abdominal pain, nausea, vomiting, or changes in bowel habits may suggest EBV involvement in the gastrointestinal tract, a common site for PTLD in transplant patients.
A palpable spleen or liver, or abnormal imaging results, may indicate EBV-related organ involvement. Elevated liver enzymes can also occur with EBV hepatitis.
Seizures, confusion, altered mental status, or focal neurological deficits may indicate EBV encephalitis or meningitis. Immediate medical evaluation and testing are critical to prevent life-threatening outcomes.
The EBV PCR test is essential for early screening, diagnosis, and detection of EBV infection and related complications.
The test confirms active EBV infection when symptoms such as fever, lymphadenopathy, fatigue, or organ-specific issues like hepatitis or encephalitis are present.
In transplant recipients, regular EBV PCR testing detects viral reactivation before PTLD develops. Early detection enables reduction of immunosuppression and preemptive therapy.
Before organ or stem cell transplantation, both donor and recipient EBV status (serology) are assessed. EBV-naïve recipients who receive an EBV-positive organ are at the highest risk for severe complications.
In immunocompromised individuals, including those with HIV or undergoing chemotherapy, routine testing helps detect EBV reactivation before symptoms develop, allowing for preemptive treatment.
A positive result may lead to reduced immunosuppression or initiation of antiviral agents, such as rituximab for PTLD. A negative result may rule out EBV as the cause of symptoms.
Serial tests showing conversion from positive to negative can confirm that therapy, such as rituximab or reduced immunosuppression, has effectively controlled EBV.
The EBV PCR test detects Epstein-Barr Virus (EBV) DNA in blood or other body fluids. Unlike quantitative tests, it confirms only whether the virus is present or absent. This is especially useful for early diagnosis, screening immunocompromised patients, and guiding timely clinical decisions before symptoms worsen.
|
Parameter |
Description |
|
EBV DNA Detection |
Determines whether EBV genetic material is present in the sample. |
|
Infection Status |
Positive = active EBV infection, reactivation, or EBV-driven PTLD. Negative = no detectable virus. |
|
Clinical Decision Point |
Helps guide immunosuppression reduction, antiviral therapy, or rituximab treatment based on the presence/absence of the virus. |
This test is primarily recommended for individuals at high risk of EBV-related complications due to immunosuppression.
Patients who have undergone solid organ transplantation are at high risk of EBV reactivation due to lifelong immunosuppression. EBV can cause post-transplant lymphoproliferative disorder (PTLD), a serious and potentially fatal lymphoma. Regular EBV monitoring enables early intervention and supports long-term transplant outcomes.
Individuals who have received stem cell or bone marrow transplants are highly vulnerable to EBV reactivation, especially within the first 6 to 12 months after the procedure. EBV can cause PTLD in this group, with a high mortality rate if not detected early. Preemptive monitoring is standard care.
People living with HIV, especially those with low CD4 counts (below 200 cells/µL), are at increased risk for EBV-related lymphomas, such as Burkitt lymphoma or primary CNS lymphoma. EBV PCR helps screen for reactivation and guide treatment.
Patients receiving immunosuppressive treatments, such as chemotherapy, biologics like rituximab or anti-thymocyte globulin, or high-dose corticosteroids, are more susceptible to EBV reactivation. Monitoring helps manage risks and adjust treatment plans.
Individuals who develop fever, lymphadenopathy, weight loss, or organ dysfunction after transplantation should be tested for EBV to rule out PTLD. Early detection is critical because PTLD can progress rapidly.
Immunocompetent individuals with persistent swollen lymph nodes, fever, or weight loss may also require EBV testing to rule out chronic active EBV or EBV-associated lymphoma.
Although rare, congenital EBV infection may present with low birth weight, jaundice, or hepatosplenomegaly. Testing helps confirm the diagnosis and guide management.
Understanding the basic specifications of the EBV PCR test helps patients and caregivers prepare and know what to expect. The test is straightforward, requires no special preparation, and can be performed using various clinical samples based on the patient’s condition.
|
Parameter |
Details |
|
Test Name |
EBV (Epstein-Barr Virus) PCR |
|
Also Known As |
Epstein-Barr Virus DNA PCR () |
|
Sample Type |
Blood (EDTA tube), CSF, or tissue biopsy |
|
Gender |
Both |
|
Age Group |
All |
|
Fasting Required |
No |
|
Report Time |
24-48 Hours |
|
Home Collection |
Available |
Preparing for the EBV PCR test is straightforward. Follow these guidelines to ensure accurate results and a smooth sample collection experience.
Several clinical and technical factors can affect the accuracy and interpretation of an EBV PCR test. Understanding these variables helps clinicians avoid misdiagnosis, especially in high-risk patients.
|
Factor |
Effect on Result |
|
Timing of Test |
Testing too early after reactivation may give false negative. Serial testing is often needed. |
|
Immunosuppression Level |
Heavier immunosuppression → higher risk of EBV reactivation → more likely positive. |
|
Antiviral Prophylaxis |
Acyclovir or ganciclovir may suppress EBV levels below detection → false negative. |
|
Sample Type |
Blood detects viremia; CSF may be positive in CNS lymphoma even if blood is negative. |
|
Sample Handling |
Delayed processing can degrade DNA and cause false negative. |
The EBV PCR test indicates whether Epstein-Barr Virus (EBV) DNA is present in the sample. Proper interpretation requires understanding the clinical context, patient risk factors, and symptoms.
|
Result |
Interpretation |
Next Steps |
|
Not Detected |
No active EBV infection (or viral load below test detection limit). |
Monitor clinically; repeat testing if symptoms persist or if the patient is high-risk (e.g., transplant recipient). |
|
Detected |
Active EBV infection (primary, reactivation, or EBV-driven PTLD). |
Consider reducing immunosuppression, perform quantitative PCR for viral load; assess for PTLD (imaging, biopsy), and consult the transplant team. |
Note: A “Detected” result should always be interpreted in clinical context, considering symptoms, immune status, and organ function. In transplant patients, even low-level detection may require preemptive therapy, such as reduced immunosuppression or rituximab.
Choosing the right diagnostic provider is essential for accurate results, timely diagnosis, and a seamless healthcare experience. MAX@Home combines advanced diagnostic technology with patient-focused services.
Sample collection is performed by highly trained and certified phlebotomists who follow strict infection control and hygiene protocols. This ensures a safe, professional experience, which is especially important for immunocompromised patients.
All samples are processed in NABL-accredited laboratories that follow stringent quality control measures to ensure high accuracy, consistency, and reliability.
MAX@Home uses advanced real-time PCR technology, recognized for high sensitivity and specificity, enabling detection of low levels of EBV DNA for early diagnosis.
Schedule your EBV test at a convenient time with doorstep sample collection, eliminating hospital visits and reducing infection risk for immunocompromised individuals.
From booking to timely sample collection and rapid digital report delivery, MAX@Home provides comprehensive support throughout the process.
Reports are typically delivered within 24 to 48 hours, enabling doctors to initiate timely treatment or further investigations.
Supported by Max Healthcare’s clinical expertise, MAX@Home brings hospital-grade diagnostics to your doorstep.
The service is especially beneficial for transplant recipients, cancer patients, and HIV patients who require frequent monitoring but should minimize hospital exposure.
Early detection of EBV can prevent life-threatening complications, such as PTLD, in transplant recipients and immunocompromised patients. Do not wait for symptoms to worsen.
Read More
You've selected items to compare.
View All
MAX@Home is one of Gurgaon’s leading providers of diagnostic services, with lab-test centres located across all major localities in the city.